

Cytarabine

Essential medicine status

General description

Cytarabine is a pyrimidine nucleoside analogue antineoplastic agent used in the treatment of leukaemias and lymphomas.

INN

Cytarabine

ATC codes

[L01BC01](#)

Medicine type

Chemical agent

EML status history

First added in 1979 ([TRS 641](#)) for [Lymphoid leukaemia, not elsewhere classified](#)

Added in 1979 ([TRS 641](#)) for [Myeloid leukaemia](#)

Added in 1979 ([TRS 641](#)) for [Acute myeloid leukaemia with recurrent genetic abnormalities](#)

Added in 1979 ([TRS 641](#)) for [Burkitt lymphoma including Burkitt leukaemia](#)

Added in 1979 ([TRS 641](#)) for [Unspecified malignant neoplasms of ill-defined or unspecified sites](#)

Removed in 2015 ([TRS 994](#)) for [Unspecified malignant neoplasms of ill-defined or unspecified sites](#)

Added in 2023 ([TRS 1049](#)) for [Anaplastic large cell lymphoma, ALK-positive](#)

Added in 2023 ([TRS 1049](#)) for [Anaplastic large cell lymphoma, ALK-negative](#)

Added in 2023 ([TRS 1049](#)) for [Langerhans cell histiocytosis](#)

Wikipedia

[Cytarabine](#)

DrugBank

[Cytarabine](#)

Recommendations

Section

Cytotoxic medicines

- Parenteral > General injections > unspecified: 100 mg in vial powder for injection; 100 mg per mL in vial
- Parenteral > General injections > unspecified: 100 mg in vial powder for injection

Indications

[Lymphoid leukaemia, not elsewhere classified](#) [Myeloid leukaemia](#) [Acute myeloid leukaemia with recurrent genetic abnormalities](#) [Burkitt lymphoma including Burkitt leukaemia](#) [Unspecified malignant neoplasms of ill-defined or unspecified sites](#) [Anaplastic large cell lymphoma, ALK-positive](#) [Anaplastic large cell lymphoma, ALK-negative](#) [Langerhans cell histiocytosis](#)